The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH. We (1) characterized the plasma BA profile in biopsy-proven NAFL and NASH and compared to controls and (2) related the plasma BA profile to liver histologic features, disease activity, and fibrosis. Liquid chromatography/mass spectrometry quantified BAs. Descriptive statistics, paired and multiple group comparisons, and regression analyses were performed. Of 86 patients (24 controls, 25 NAFL, and 37 NASH; mean age 51.8 years and body mass index 31.9 kg/m 2 ), 66%
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The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH. We (1) characterized the plasma BA profile in biopsy-proven NAFL and NASH and compared to controls and (2) related the plasma BA profile to liver histologic features, disease activity, and fibrosis. Liquid chromatography/mass spectrometry quantified BAs. Descriptive statistics, paired and multiple group comparisons, and regression analyses were performed. Of 86 patients (24 controls, 25 NAFL, and 37 NASH; mean age 51.8 years and body mass index 31.9 kg/m 2 ), 66%
were women. Increased total primary BAs and decreased secondary BAs (both P < 0.05) characterized NASH. Total conjugated primary BAs were significantly higher in NASH versus NAFL (P 5 0.047) and versus controls (P < 0.0001). NASH had higher conjugated to unconjugated chenodeoxycholate (P 5 0.04), cholate (P 5 0.0004), and total primary BAs (P < 0.0001). The total cholate to chenodeoxycholate ratio was significantly higher in NAFLD without (P 5 0.005) and with (P 5 0.02) diabetes. Increased key BAs were associated with higher grades of steatosis (taurocholate), lobular (glycocholate) and portal inflammation (taurolithocholate), and hepatocyte ballooning (taurocholate). Conjugated cholate and taurocholate directly and secondary to primary BA ratio inversely correlated to NAFLD activity score. A higher ratio of total secondary to primary BA decreased (odds ratio, 0.57; P 5 0.004) and higher conjugated cholate increased the likelihood of significant fibrosis (F2) (P 5 0.007). Conclusion: NAFLD is associated with significantly altered circulating BA composition, likely unaffected by type 2 diabetes, and correlated with histological features of NASH; these observations provide the foundation for future hypothesis-driven studies of specific effects of BAs on specific aspects of NASH. (HEPATOLOGY 2018;67:534-548)
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N onalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and is closely associated with insulin resistance and type 2 diabetes mellitus. (1) The histological spectrum of NAFLD extends from a fatty liver to steatohepatitis. Nonalcoholic steatohepatitis (NASH) progresses to cirrhosis in 15%-20% of subjects over a time frame of 15-20 years. (2) NASH is projected to become the leading Abbreviations: BA, bile acid; CA, cholate; CDCA, chenodeoxycholate; CI, confidence interval; DCA, deoxycholate; FXR, farsenoid X receptor; GCA, glycocholate; GCDCA, glycochenodeoxycholate; LI, lobular inflammation; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; OR, odds ratio; TCA, taurocholate; TCDCA, taurochenodeoxycholate; UDCA, ursodeoxycholate.
etiology of both hepatocellular cancer and end-stage liver disease requiring liver transplantation. (3, 4) The pathogenesis of NASH is incompletely understood, and there are currently no approved therapies for NASH.
In recent years, there has been considerable interest in the potential role of bile acids (BAs) in the development of NASH. BAs are derived from cholesterol through a classical cytochrome 7a hydroxylase pathway and a mitochondrial cytochrome 27a hydroxylase in the liver and secreted into the bile. Upon entry into the intestine, they assist in lipid emulsification and absorption. BAs are also modified by intestinal bacteria, are actively reabsorbed from the ileum, and undergo several cycles of enterohepatic circulation daily. (5) They are further modified after first-pass metabolism, largely as conjugates of glycine. BA synthesis from cholesterol is stimulated by activation of the orphan nuclear receptor liver X receptor and inhibited by their interaction with farsenoid X receptor (FXR). Hydrophobic dihydroxylic and monohydroxylic BAs, e.g., chenodeoxycholate (CDCA) and lithocholate, respectively, are potent activators of FXR and display more active FXR agonistic effects compared to trihydroxylic BAs such as taurocholate (TCA). (6, 7) Over the last decade, BAs have been shown to play a central role in metabolic homeostasis and to affect insulin sensitivity. (8, 9) The insulin-sensitizing effects of BAs are mediated through interaction with their receptor, FXR. Insulin resistance, the principal risk factor for NAFLD, (10) is associated with a shift in the circulating BA profile toward a more trihydroxylic one which has weaker FXR agonist effects compared to more hydrophobic BAs. (11, 12) Obeticholic acid (6a-ethyl-chenodeoxycholic acid) is a synthetic BA and a potent FXR agonist. (13) Obeticholic acid improves glucose disposal in subjects with type 2 diabetes and the key histological features of NASH. (14) These provide a rationale to evaluate the role of BAs in NAFLD and have been reviewed in depth. (15, 16) Initial studies in subjects with NAFLD provided discrepant results on the total BA levels in these subjects; one of these was in subjects undergoing bariatric surgery. (17) In the latter study, total BAs were not increased, and no relationship with NAFLD histology was found. This is, however, discrepant with the larger body of literature on metabolic syndrome. (18, 19) There is, therefore, a need to better characterize the pattern of BAs as well as BA conjugation and metabolism in various phenotypes of NAFLD and the relationship of these changes to the severity of the liver disease in order to generate hypotheses to better understand the potential role of BAs in the genesis and progression of NASH, the phenotype that is most likely to progress to cirrhosis.
The objectives of this study were therefore to (1) compare and characterize the plasma BA profile in nonalcoholic fatty liver (NAFL) and NASH to controls with no known liver disease, (2) relate plasma BA profile to liver histology (steatosis, inflammation, hepatocellular ballooning, fibrosis) and disease activity and stage, and (3) evaluate the status of FXR signaling pathway in NAFL and NASH.
Materials and Methods
This was a prospective cross-sectional study of the BA profile in NAFLD. Subjects with NAFLD were recruited from fatty liver disease and primary care clinics at the authors' institution. All subjects provided informed consent, and the study was approved by the Virginia Commonwealth University institutional review board (1960) . All of the data were analyzed by the authors, who have fully reviewed the data and approved the manuscript.
Two groups of subjects were recruited for these studies. They included subjects with NAFLD and controls without evidence of NAFLD. NAFLD was diagnosed by a liver biopsy in all instances and further categorized as NAFL and NASH based on NASH Clinical Research Network criteria. (20) Plasma samples
were obtained in a fasted state in the morning within 90 days of the liver biopsy in all cases. Controls had no clinical, biochemical, or imaging evidence of fatty liver disease. High-throughput profiling of BAs was performed using liquid chromatography/mass spectrometry. BA metabolite data in original scale in terms of raw area counts was normalized by median centering. Missing values were imputed with the lower limit of detection for a given metabolite. When 30% of values were missing, data were excluded from analyses. The peak and area under the curve for individual analytes were related to validated library standards to compute BA levels, which are read out as related to these library standards. The proportion of individual BAs as a function of total BAs was calculated using total measured scaled imputed values and ratios. Additional details regarding study participants, procedures, liver histologic and fibrosis assessment, BA profiling studies, bioinformatics, and statistical analyses are provided in the Supporting Information.
Results

CHARACTERISTICS OF THE STUDY POPULATION
Eighty-six patients including controls (n 5 24), NAFL (n 5 25), and NASH (n 5 37) were studied. Participants had a mean age of 51.8 years and were predominantly women (66.3%) and obese (mean body mass index 5 31.9 kg/m 2 ). Patients with NAFL and NASH were older and heavier compared to controls. A stepwise increase in amino alanine aminotransferase levels was noted from controls to NAFL to NASH (P < 0.0001). Also, as expected, subjects with NAFL or NASH had a higher prevalence of metabolic comorbidities (i.e., hypertension, hyperlipidemia, and diabetes). The clinical, demographic, and histologic details are summarized in Supporting Table S1 .
THE PLASMA BA PROFILE IS SIGNIFICANTLY ALTERED IN NASH
Total plasma primary BAs (mean abundance relative to fixed library standard) increased in a stepwise manner from control to NAFL to NASH (P < 0.04 NASH versus controls) (Fig. 1A) . Conversely, a stepwise reciprocal decrease in total secondary BAs was observed from controls to NAFL to NASH (Fig. 1A) . A heat map display (Fig. 1B) shows the means for each measured plasma BA in the respective study groups. Plasma 7a-hydroxy-3-oxo-4-cholestenoic acid levels were comparable without significant changes among the three study groups (Supporting Fig. S1A ). Patients with NASH had significantly increased plasma glycocholate (GCA) and TCA (P < 0.05), glycochenodeoxycholate (GCDCA) and taurochenodeoxycholate (TCDCA; P < 0.05), and glycoursodeoxycholate and tauroursodeoxycholate (P < 0.05). The latter is noteworthy because none of the subjects were taking ursodeoxycholate (UDCA) as pharmacological therapy. Although 33 subjects were taking a statin, the data for those on statins were qualitatively similar to the data for those not on statins. Further, the results were similar when the group without statins was compared to the whole group including those on statins. The results are therefore shown for the entire group. None of the subjects were taking glucagon-like peptide 1 agonists.
Plasma Primary BA Profile in NAFL and NASH
The abundance of cholate (CA) and CDCA, measured as relative to a library standard, was not significantly different across the groups, although there was a trend for decreased CDCA in NASH (Supporting Fig. S1B,C) . Together, the total primary unconjugated bile acids (CA 1 CDCA) was not different across the study groups (Supporting Fig. S1D ).
Plasma GCA and TCA increased in a stepwise manner from controls to NAFL to NASH, with a marked increase in NASH versus controls (P < 0.0001 for both; Fig. 1C,D) . Similarly, patients with NASH had significantly higher plasma TCDCA (P 5 0.05) and GCDCA (P < 0.0006) (Fig. 1E,F) . While there was only an apparent trend for a stepwise increment in total conjugated CDCA (GCDCA 1 TCDCA) from controls to NASH (Supporting Fig. S1E ), the total conjugated CA was significantly higher in NASH compared to both controls (P < 0.0001) and NAFL (P < 0.01) ( Fig. 2A) . Taken together, the total conjugated primary BAs (GCA 1 TCA 1 GCDCA 1 TCDCA) was significantly higher in those with NASH compared to NAFL (P < 0.047) and controls (P < 0.0001) (Fig. 2B) .
Interestingly, there was a stepwise increase in the median ratios (0.97 in controls versus 1.72 in NAFL versus 3.41 in NASH) of conjugated to unconjugated CA, with a marked difference in NASH versus FIG. 1. Plasma BA profile is significantly altered in NASH. Data presented as box and whiskers Tukey plot with median and staggered outliers. (A) Stack bar plot representing proportion of total primary and secondary BAs and box and whisker plot for total primary BAs. (B) Heat map display of the spectrum of BA profile across three study groups with orange/red as larger and blue/green as smaller measurements. The green color on the side bar along the left of the heat map indicates P < 0.05. (C-F) Glycine and taurine conjugates of cholate and chenodeoxycholate. *P < 0.05, ***P < 0.001, ****P < 0.0001. controls (P 5 0.0004) (Fig. 2C) . Similarly, compared to controls, subjects with NASH had a significantly higher (P 5 0.04) median ratio (0.88 in controls versus 1.27 in NAFL versus 5.95 in NASH) for conjugated to unconjugated CDCA (Fig. 2D) . Moreover, the median ratios of total conjugated to unconjugated Patients with NASH also demonstrate significantly increased proportions of conjugated to unconjugated (C) CA, (D) CDCA, and (E) primary BAs. BA levels were measured against known internal standards in global metabolomics profile and provide a relative quantitative measure of the BAs relative to the library standards across samples. *P < 0.05, **P < 0.01, ****P < 0.0001. primary BAs were 1.21 in controls versus 2.12 in NAFL versus 5.02 in NASH, which was highly significant for NASH versus controls (P < 0.0001; Fig. 2E ).
The median ratios of the total CA (CA 1 GCA 1 TCA) to total CDCA (CDCA 1 GCDCA 1 TCD CA) were 0.99 in controls versus 2.63 in NAFL versus 4.10 in NASH (Fig. 3A) , with a statistically significant increase in NASH compared to controls (P 5 0.003). Notably, when NAFLD (all subjects with NAFL or NASH) was stratified as with and without diabetes, the median ratios of total CA to CDCA were higher for NAFLD for both those without (P 5 0.005) and those with (P 5 0.02) diabetes compared to controls (median ratio 0.91 in controls versus 3.40 in NAFLD without diabetes versus 3.38 in NAFLD with diabetes; Fig. 3B ). These data indicate that the observed changes in NASH cannot be attributed to the underlying diabetes.
Plasma Secondary BA Profile in NAFL and NASH
Patients with NASH when compared to controls had significantly lower total plasma secondary BAs ( Fig. 3C ; P 5 0.035) and a resultant significantly lower total secondary to primary BA ratio ( Fig. 3D ; P 5 0.03). However, unconjugated deoxycholate (DCA), a secondary BA derived from CA, was higher and approached significance in patients with NASH versus controls ( Fig.  3E ; P 5 0.05). The secondary conjugated BAs glycodeoxycholate and taurodeoxycholate, as well as glycolithocholate and taurolithocholate, were comparable across the three study groups (Supporting Fig. S2A-D) . Similarly, no significant differences were observed for conjugated DCA, conjugated lithocholate (data not shown), and overall total conjugated secondary BAs among the study groups (Supporting Fig. S2E,F) . Plasma UDCA was not significantly different among the study groups. In contrast, subjects with NASH had significantly higher conjugated UDCA versus NAFL (P 5 0.01) and controls (P 5 0.0005) (Fig. 3F) .
Changes in Plasma BAs in NAFLD Versus Controls
Taken together, subjects with NAFLD (NAFL or NASH) recapitulated the same trends seen with NASH versus controls noted above. Specifically, the total plasma primary BA value was significantly increased in subjects with NAFLD versus controls (P 5 0.024). A mirror image decrease in the total plasma secondary BAs was present in NAFLD compared to controls (P 5 0.024). As a result, the ratio of total plasma secondary BA to primary BA was significantly lower (P 5 0.024, NAFLD versus control).
The GCA and TCA levels were significantly higher in patients with NAFLD versus controls (both P < 0.0001). NAFLD was also associated with a significantly increased GCDCA (P 5 0.0006). The conjugated CA and total conjugated BAs were also significantly increased in NAFLD (P < 0.0001 and P 5 0.003, respectively). Subjects with NAFLD had significantly higher hydrophilic trihydroxy-BAs (P 5 0.01 versus controls) and a lower hydrophobic to hydrophilic ratio (P 5 0.003 versus controls). Fig. 4A ,B. Plasma TCA was significantly higher in grade 3 versus lower grades of steatosis ( Fig. 4C; Fig. 4D ). In contrast, plasma CDCA was significantly lower in grade 3 versus lower grades of steatosis ( Fig. 4E ; P 5 0.04). A higher grade of steatosis also was associated with a significantly increased ratio of conjugated to unconjugated CA ( Fig. 4F ; P 5 0.048).
There Is a Differential Effect of Primary Versus Secondary BAs on Severity of Lobular and Portal Inflammation
Lobular inflammation (LI) was graded from 0 to 3 using the NASH Clinical Research Network protocol. (20) Increasing total primary BAs (Fig. 5A ) and decreasing total secondary BAs (Fig. 5B) 
Plasma Primary and Secondary BAs Are Both Related to Hepatocyte Ballooning
Hepatocyte ballooning grades 0-2 were dichotomized for analysis purposes into no ballooning and any grade of ballooning. A significantly higher plasma TCA was seen in patients with any grade of ballooning compared to those without hepatocyte ballooning ( Fig.  5D ; P 5 0.017). On nominal logistic multiple regression analyses several BAs showed a significantly higher likelihood of hepatocyte ballooning with false discovery rate log worth P values for GCA (50.026), TCA (50.006), GCDCA (50.003), and DCA and glycolithocholate (50.001 for both).
An Increase in Primary BAs Is Directly Related to the NAFLD Activity Score
The NAFLD activity score (NAS) was analyzed first as a dichotomous (NAS 3 versus 4) variable. Plasma TCA was significantly higher in patients with NAS 4 versus 3 (Supporting Fig. S3A ; P 5 0.017). Increasing total primary BAs was associated with higher likelihood of NAS 4 ( Fig. 6A ; P 5 0.04; range OR, 11; 95% CI, 1.2-133). Similarly, a significantly higher probability of NAS 4 (R 2 5 0.05, P 5 0.04) was observed with increasing total conjugated CA (GCA 1 TCA) (Fig. 6B) . Conversely, increasing ratio of total secondary to primary BAs decreased the odds of NAS 4 by 42% (OR, 0.58; 95% CI, 0.3-0.9; P 5 0.01; Fig. 6C ).
Upon least square regression analyses for NAS as a continuous variable (0-8), increasing plasma TCA and conjugated CA (GCA1TCA) were directly related to NAS (R 2 5 0.11, P 5 0.01 and R 2 5 0.10, P 5 0.02, respectively; Fig. 6D,E) . In contrast, the secondary to primary BA ratio was inversely related (R 2 5 0.08, P 5 0.03) to the NAS (Fig. 6f) .
Plasma BA Profile and Relationship With Fibrosis
The profile of plasma BAs in those with clinically significant fibrosis (F2 and higher) versus lower stages and a heat map display are shown in Fig. 7A ,B. Patients with clinically significant fibrosis (F2) had significantly higher plasma GCA (Supporting Fig.  S3B ; P 5 0.003) and TCA (Supporting Fig. S3C ; P 5 0.001). Increasing GCA, TCA, and total conjugated CA (GCA 1 TCA) were directly associated with an increased likelihood of clinically significant fibrosis (F2) ( Fig. 7C-E ; R 2 5 0.08, P 5 0.005; R 2 5 0.04, P 5 0.036; and R 2 5 0.07, P 5 0.007, respectively). In contrast, the probability of clinically significant fibrosis (F2) was significantly lower and decreased by 43% with increasing ratio of total secondary to primary BAs ( Fig. 7F ; R 2 5 0.08; OR, 0.57; 95% CI, 0.34-0.85; P 5 0.004).
NAFLD Is Associated With Decreased FXR Expression and Signaling
The status of FXR signaling was assessed from fasting fibroblast growth factor 19 levels and hepatic mRNA expression of several FXR targets such as small heterodimer partner, bile salt export pump, and phospholipid transport protein, which all showed a decreasing trend, and a significantly increased cytochrome 7a hydroxylase (Supporting Fig. S4 ). In keeping with decreased FXR signaling in the liver, fasting fibroblast growth factor 19 levels also tended to decrease in subjects with NASH with stage 2 fibrosis onward.
Plasma BA profiles in histologically defined NASH and NAFL compared to the controls are summarized in Fig. 8 .
Discussion
There is growing interest in the role of BAs in the genesis and progression of NASH. In this study, multiple abnormalities in the profile of circulating BAs in subjects with NAFL and NASH are described. Importantly, several associations with the histological phenotype and severity of the disease were identified. While these data do not reflect causality, they do provide a foundation for future hypothesis-driven studies of specific effects of BAs on specific aspects of NASH.
A key finding is an increase in total primary BAs in subjects with both NAFL and NASH, with the findings in NASH reaching statistical significance. This could be due to increased synthesis of primary BAs and/or decreased conversion to secondary BAs in the intestine. An elevated cytochrome 7a hydroxylase expression level along with statistically nonsignificantly altered 7a-hydroxy-3-oxo-4-cholestenoic acid levels suggests that BA synthesis is largely intact. Furthermore, the increase in conjugated GCDCA and TCDCA indicates that the mitochondrial cytochrome 27a hydroxylase pathway is still intact in NASH. A decrease in bile excretion, supported by the observation of decreased bile salt export pump, is another potential reason for increased circulating levels of primary BAs but does not explain why secondary BAs are decreased.
An alternate possibility is that a decrease in intestinal dehydroxylation of primary BAs and reduced formation of secondary BAs results in enhanced primary BA synthesis. These functions are dependent on the intestinal microbiota and have been extensively characterized. (21) (22) (23) Another conceivable reason for increased plasma primary conjugated BAs in NASH may be due to decreased enterohepatic circulation and/or a decrease in small intestinal bacteria capable of deconjugating primary BAs. While changes in the intestinal microbiome have been reported in NASH, (24) (25) (26) (27) they do not yet provide mechanistic information regarding the linkage of these changes with development of NASH. Specifically, the changes in the BA-metabolizing microbiome are not well described and need to be characterized as a research priority in this field. It is interesting to note the increase in conjugated UDCA even in the absence of exogenous intake that most likely reflects intestinal conversion of the excess TCDCA and GCDCA to their respective UDCA conjugates. These changes suggest that with more severe forms of fatty liver disease such as NASH, there is a shift toward more hydrophilic forms of BAs, i.e., UDCA conjugates, (28) to mitigate BAmediated hepatotoxicity. From a functional point of view, the increase in total CA versus CDCA is likely to be highly relevant to the development of NASH. CA and its conjugates are less potent agonists for FXR compared to CDCA and its conjugates. (7) This would be expected to promote insulin resistance, a hallmark of prototypical NASH. (10) CDCA and its conjugates are also more potent ligands for intestinal TGR5 receptors on L cells. (29) Upon activation of TGR5 receptors, L cells release glucagonlike peptide 1, which has pleiotropic effects in NASH including increased insulin sensitivity and promoting beta-cell function. (30) (31) (32) (33) Insulin resistance and the combination of increased free fatty acid delivery to the liver and increased de novo lipogenesis are both involved in the genesis of a fatty liver. (10, 34) It is therefore not surprising that higher levels of conjugated CA were associated with greater insulin resistance and hepatic steatosis in this study.
A novel and potentially important finding is that the changes in the BA profile are most severe in those with NASH and regardless of the presence of diabetes in NAFLD. In prior studies of changes in BAs in those with diabetes, there was no systematic assessment of underlying presence, phenotype, or severity of NASH. (11, 12, 35, 36) These observations raise the possibility that such changes occur early and reflect a maladaptive hepatic response to increased lipid and carbohydrate load to hepatocytes with further worsening insulin resistance, thereby setting the stage for eventual development of type 2 diabetes. If so, this would provide a potential explanation for the known increased risk of development of type 2 diabetes mellitus in those with NASH without diabetes. (18) Formal testing of this hypothesis will require either longitudinal assessments in cohorts with well-defined clinical and hepatic phenotyping along with bile acid measurements or assessment in animal models of NASH that are relevant to human disease.
The relationship of conjugates of CA with the NAS indicate that BAs contribute to disease activity but that the mechanisms underlying the individual disease components may or may not be identical. It is interesting to note the differential relationship between primary and secondary BAs with respect to lobular versus portal inflammation, respectively. The mechanistic basis for this is not yet known; the possibility that these reflect metabolic zonation within the liver and changes in the microenvironment with altered BA profile is logical and worth exploration in future studies. However, in contrast to these findings, both primary and secondary BAs were related to the presence of hepatocyte ballooning, a marker of cell injury. (37) The low false discovery rates indicate that these are indeed robust and real findings. There is indeed a plethora of literature on the cytotoxic effects of BAs, which represent the most likely explanation for these findings.
The relationship between conjugated CA and fibrosis stage is also novel and very noteworthy. As previously noted, these BA species are not strong FXR agonists. (7) However, the decrease in secondary BAs, the natural endogenous agonists of FXR, and their inverse relationship to fibrosis stage coupled with the antifibrotic effects of the FXR agonist obeticholic acid suggest that decreased FXR signaling is likely to be important in disease progression in NASH. What is less clear is if this is a direct effect on hepatic stellate cells given the current controversy about the expression (or lack thereof) of FXR on these cells. (38) An alternate explanation could be related to the observed relationship of CA and its conjugates on hepatocellular injury, ballooning, and inflammation, which are proximal drivers of stellate cell activation. In that case, an increase in secondary BAs or use of FXR agonists could reverse this pathophysiological cascade. Together, they provide a biologically plausible model for the role of BAs in fibrosis progression in NASH.
In summary, we have demonstrated significant changes in composition of circulating BAs in NAFLD with the greatest changes in NASH. These changes occur even in the absence of type 2 diabetes and are associated with the histological features of NASH. While these findings are correlative, they provide the foundational basis for development of future focused mechanistic hypotheses, which can be further leveraged to treat the condition.
